Geron (GERN) Alert: Johnson Fistel Launches Investigation into Geron Corporation; Investors Encouraged to Contact Firm
SAN DIEGO, Oct. 29, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Geron Corporation ("Geron") (NASDAQ: GERN) on behalf of investors. Geron is a biopharmaceutical company.
Specifically, the investigation seeks to determine whether certain statements regarding the results of a clinical drug study of imetelstat called IMbark were false and misleading when made. Imetelstat was intended to treat certain cancers that occur in bone marrow and the IMbark study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis. Geron was developing imetelstat in partnership with Janssen Biotech Inc. ("Janssen"), a division of Johnson & Johnson. On September 27, 2018, the company issued a press release stating that patients in the IMbark study had shown only 10% spleen response rate and 32% symptom response rate. The company also announced that Janssen had terminated its partnership with the Geron for the development of imetelstat. Following this news, the price of Geron's stock dropped from $6.23 to $2.31 on September 27, 2018, a decrease of over 62%.
If you lost money, realized or unrealized on your Geron investment, and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) by email or phone at 619-814-4471. If emailing, please include a phone number.
Additionally, you can [click here to join this action]. There is no cost or obligation to you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
SOURCE Johnson Fistel, LLP